Four difficulties in traditional Chinese medicine enterprises

The new pharmacopoeia will be implemented soon Before and after the implementation of the new pharmacopoeia, there may be some "strange" phenomena in the field of traditional Chinese medicine The medicinal materials whose prices are going to rise sharply are mainly concentrated in some wild varieties which are lack of resources in producing areas, limited in market stock, and the consumption at the demand end is not reduced, while the domestic varieties have not yet made breakthrough for a while The varieties whose prices will fall sharply are mainly concentrated on some non genuine medicinal materials Most of the reasons for the falling price of these "medicinal materials" are the result of the blind introduction of medicinal materials by farmers regardless of their geographical expansion In addition, due to the different growing areas of the same variety in the same real estate, the content of corresponding components is different, and some medicinal materials will also show polarization in price For example, Baoding, Hebei Province, is a genuine producer of smallpox, which can be sold for 16 yuan / kg Bozhou, Anhui Province, is also the genuine origin of smallpox powder The smallpox powder here has been well-known since ancient times, and has been known as one of the "four BOMs" in the pharmaceutical industry for a long time However, due to the low level of extracts that must meet the pharmacopoeia standard, no buyer can be found for 8 yuan / kg Is it only the same variety growing in the same place of origin that will not lead to price gap? Obviously not, even for the same variety growing in the same place of origin, with the 2020 Pharmacopoeia will carry out the detection of heavy metals and agricultural residues for more varieties of medicinal materials, there will inevitably be new phenomena in the future - the prices of agricultural residues and medicinal materials with no heavy metals exceeding the standard will rise, while the prices of agricultural residues and varieties with heavy metals exceeding the standard will inevitably decline For the above phenomenon, experts said frankly: no need to make a big fuss, this is a kind of phenomenon that occurs from the qualitative upgrade to the price leap, which is very normal Since the reform and opening up, in the environment of market economy, no matter what industry in the society, there are more or less "makers", "speculators" and "pressure merchants" Similarly, the traditional Chinese medicine industry is no exception The "makers" in the traditional Chinese medicine industry refer to those capital tycoons who artificially interfere with the market, maliciously monopolize certain varieties, and graft the injury or high price to the vast number of drug dealers and consumers after a lot of speculation and bid up to the sky high price The "speculators" in this industry mostly refer to the peddlers who follow behind the "makers" to chase after the wind and drive out the fart, and "suck low and throw high" some kinds of medicinal materials As for the "pressure goods merchant", it is another kind of faction, which is obviously different from the "dealer, speculator" in the industry In order to reduce the risk to the lowest level, they usually don't earn fast money In order not to attract the attention of the public, these people do not like to monopolize some kinds of medicinal materials The price is low, and the price is high It is quietly sold out The quantity of goods is never full, and the profit is enough It is the consistent pursuit and goal of the "pressure supplier" in the traditional Chinese medicine industry to keep the position of "water reservoir" and "leverage balance" without arrogance and momentum, and to build and close the position quietly without leaving traces Of course, in recent years, with the severe crackdown and strengthened management of relevant departments, there are few "makers" in the market of traditional Chinese medicine industry However, there are some "small speculators" who follow the trend of traditional Chinese medicine market and "oppressors" who act quietly With the implementation of the new pharmacopoeia in 2020 next year, what changes will those "speculators and dealers" in the drug market usher in? In the new pharmacopoeia, the requirements of drug quality standards are constantly enhanced and improved, for example, heavy metals and agricultural residues are added to some Chinese herbal medicines and Chinese herbal pieces Therefore, some "speculators" in the current drug market will be very cautious about this In order not to cause their own hoarding of varieties, in the new pharmacopoeia because of the "difficult to pass the inspection" big fall, resulting in the final can not get rid of the realization of profits, these people will certainly rush to make a large-scale "clearance" flight preparation before and after the launch of the new Pharmacopoeia next year, will not be too obsessed with the market of some volatile varieties For those "pressure suppliers" who have always been relatively steady in their work, they will see the implementation of the new pharmacopoeia as an opportunity They will "store water" and "build warehouses" for some varieties in the market with lower prices and in line with the standards of the new pharmacopoeia Therefore, it is specially reminded that those downstream pharmaceutical enterprises in the traditional Chinese medicine industry, if they are the varieties with large consumption in our factory, should try their best to take precautions and try to reserve raw materials in case of emergency before the action of "pressing the suppliers" In order to avoid that the price of raw materials is too high to be contained, which will bring unnecessary economic losses to the company The pharmacopoeia is revised every five years, which has become an industry practice Every revision of pharmacopoeia is a top priority in the field of medicine, which will surely attract the attention of the industry As a large number of practitioners in the field of traditional Chinese medicine, they are even more uneasy about it Because of the increase or change of an insignificant test item in the Pharmacopoeia, it may be a challenge and an important test for every Chinese medicine enterprise The new pharmacopoeia will be implemented in the second half of next year From the perspective of enterprises, every time before the implementation of the new pharmacopoeia, it is the busiest day for enterprises Taking Chinese patent medicine enterprises as an example, some Chinese patent medicine manufacturers will seize this stage, purchase in batches, increase production, and strive to complete orders as soon as possible Because, after the implementation of the new pharmacopoeia, due to the increase or regulation of the corresponding variety inspection standards, especially in heavy metals and agricultural residues, if we don't work overtime to complete the production, it may be put in the warehouse of the original qualified raw materials, which will suddenly become unqualified For Chinese herbal medicine production enterprises, they should be the same as Chinese patent medicine production enterprises, but their practices are different Before the implementation of the new pharmacopoeia, many enterprises of Chinese herbal pieces will choose the way of selling and ordering in response to the measures Their biggest purpose is to reduce the inventory In fact, the idea is the same as that of the Chinese patent medicine manufacturers After the implementation of the new pharmacopoeia, with the increase of the corresponding test items, the raw materials in their own warehouses become unqualified as a result Both Chinese patent medicine manufacturers and Chinese Herbal Pieces manufacturers should actively deal with it, so that enterprises can better implement the new pharmacopoeia standard with light load Traditional Chinese medicine has been a treasure of the Chinese nation since ancient times However, there are many problems in the field of traditional Chinese medicine in recent years, which is also an unavoidable reality for the industry One of the most important points is the source planting of traditional Chinese medicine The origin of traditional Chinese medicine is agricultural and sideline products Only when it comes to the professional market can it be collectively called traditional Chinese medicine Originally one thing, but with a dual identity The disadvantages of different attributes bring great inconvenience to the management of industry regulators The current situation of the industry is: because the quality of products is not up to standard, the drug growers at the source of planting are in the opposite direction for the economic benefits, and they introduce them all over the place; in the middle of the regulatory level, they make every effort to put out the fire all around, but they still can't stop the poor quality of traditional Chinese medicine and herbal pieces According to statistics, in 2019, in the quality sampling of Chinese Herbal Pieces / herbs in all provinces, 1858 batches of 5865 batches of Chinese Herbal Pieces / herbs were unqualified, accounting for 31.68% In the second half of 2020, the new pharmacopoeia will continue to increase the inspection standards for heavy metals and agricultural residues of traditional Chinese medicine, Chinese herbal pieces products on the basis of the original necessary inspection items, which will be a big test for the relevant traditional Chinese medicine production enterprises and the whole industry chain in the future Some industry experts predict that in a certain period of time in the future, under the high-pressure policy at the regulatory level, it will be difficult for enterprise producers to accommodate those unqualified medicinal materials in order to avoid risks, and if the chaos of planting at the source of origin can not be contained in a short period of time, the market will encounter the phenomenon of "two ends blocking".